Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology

被引：233
|
作者：
Verheijen, Remy B. [1 ]
Yu, Huixin [1 ]
Schellens, Jan H. M. [2 ,3 ]
Beijnen, Jos H. [1 ,3 ]
Steeghs, Neeltje [2 ]
Huitema, Alwin D. R. [1 ,4 ]
机构：
[1] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Pharm & Pharmacol, Amsterdam, Netherlands
[2] Netherlands Canc Inst Antoni van Leeuwenhoek, Dept Med Oncol & Clin Pharmacol, Amsterdam, Netherlands
[3] Univ Utrecht, Dept Pharmaceut Sci, Utrecht, Netherlands
[4] Univ Utrecht, Med Ctr, Dept Clin Pharm, Utrecht, Netherlands
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2017年 / 102卷 / 05期
关键词：
CHRONIC MYELOID-LEUKEMIA; RENAL-CELL CARCINOMA; EXPOSURE-RESPONSE ANALYSIS; IMATINIB PLASMA-LEVELS; PHASE-I SAFETY; CLINICAL-RESPONSE; JAPANESE PATIENTS; CANCER-PATIENTS; POPULATION PHARMACOKINETICS; DOSE-ESCALATION;
D O I：
10.1002/cpt.787
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Despite the fact that pharmacokinetic exposure of kinase inhibitors (KIs) is highly variable and clear relationships exist between exposure and treatment outcomes, fixed dosing is still standard practice. This review aims to summarize the available clinical pharmacokinetic and pharmacodynamic data into practical guidelines for individualized dosing of KIs through therapeutic drug monitoring (TDM). Additionally, we provide an overview of prospective TDM trials and discuss the future steps needed for further implementation of TDM of KIs.
引用
收藏
页码：765 / 776
页数：12
相关论文
共 50 条
  • [1] Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
    Maud B. A. van der Kleij
    Niels A. D. Guchelaar
    Ron H. J. Mathijssen
    Jurjen Versluis
    Alwin D. R. Huitema
    Stijn L. W. Koolen
    Neeltje Steeghs
    Clinical Pharmacokinetics, 2023, 62 : 1333 - 1364
  • [2] Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
    van der Kleij, Maud B. A.
    Guchelaar, Niels A. D.
    Mathijssen, Ron H. J.
    Versluis, Jurjen
    Huitema, Alwin D. R.
    Koolen, Stijn L. W.
    Steeghs, Neeltje
    CLINICAL PHARMACOKINETICS, 2023, 62 (10) : 1333 - 1364
  • [3] Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology
    Janssen, Julie M.
    Dorlo, Thomas P. C.
    Steeghs, Neeltje
    Beijnen, Jos H.
    Hanff, Lidwien M.
    van Eijkelenburg, Natasha K. A.
    van der Lugt, Jasper
    Zwaan, C. Michel
    Huitema, Alwin D. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (03) : 494 - 505
  • [4] Therapeutic drug monitoring and tyrosine kinase inhibitors
    Herviou, Pauline
    Thivat, Emilie
    Richard, Damien
    Roche, Lucie
    Dohou, Joyce
    Pouget, Melanie
    Eschalier, Alain
    Durando, Xavier
    Authier, Nicolas
    ONCOLOGY LETTERS, 2016, 12 (02) : 1223 - 1232
  • [5] Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations
    Bella Pajares
    Esperanza Torres
    José Manuel Trigo
    María Isabel Sáez
    Nuria Ribelles
    Begoña Jiménez
    Emilio Alba
    Clinical and Translational Oncology, 2012, 14 : 94 - 101
  • [6] Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations
    Pajares, Bella
    Torres, Esperanza
    Manuel Trigo, Jose
    Isabel Saez, Maria
    Ribelles, Nuria
    Jimenez, Begona
    Alba, Emilio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (02): : 94 - 101
  • [7] Therapeutic drug monitoring in child and adolescent psychiatry -: Practical recommendations
    Gerlach, M
    Rothenhöfer, S
    Mehler-Wex, C
    Fegert, JM
    Schulz, E
    Wewetzer, C
    Warnke, A
    ZEITSCHRIFT FUR KINDER-UND JUGENDPSYCHIATRIE UND PSYCHOTHERAPIE, 2006, 34 (01): : 5 - 13
  • [8] Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets
    Yu, Huixin
    Steeghs, Neeltje
    Nijenhuis, Cynthia M.
    Schellens, Jan H. M.
    Beijnen, Jos H.
    Huitema, Alwin D. R.
    CLINICAL PHARMACOKINETICS, 2014, 53 (04) : 305 - 325
  • [9] Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets
    Huixin Yu
    Neeltje Steeghs
    Cynthia M. Nijenhuis
    Jan H. M. Schellens
    Jos H. Beijnen
    Alwin D. R. Huitema
    Clinical Pharmacokinetics, 2014, 53 : 305 - 325
  • [10] Pharmacokinetics and therapeutic drug monitoring of anticancer protein/kinase inhibitors
    Bouchet, Stephane
    Molimard, Mathieu
    THERAPIE, 2022, 77 (02): : 157 - 170
12345